Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System

Age-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System

Background: Clarithromycin is a widely used antibiotic, but its safety profile, particularly in different age groups, remains inadequately explored. Objectives: This study aims to characterize and illustrate the features of clarithromycin-related adverse events (AEs) across different age groups usin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Haiyan Mai, Zhenpo Zhang, Yankun Liang, Jingping Zheng, Ling Su
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-01-01
Series:	Therapeutic Advances in Drug Safety
Online Access:	https://doi.org/10.1177/20420986241311231
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
by: Shaimaa Elshafie, et al.
Published: (2025-01-01)

Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system
by: Yankun Liang, et al.
Published: (2024-11-01)

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004–2023)
by: Xiao-Dong Chen, et al.
Published: (2024-12-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

Cardiovascular Adverse Events Associated with Prostate Cancer Treatment: A Disproportionality Analysis from the Food and Drug Administration Adverse Event Reporting System Database
by: Connor Frey
Published: (2024-11-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study
by: Chengzhi Liu, et al.
Published: (2024-12-01)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024-11-01)

Evaluation of link between COVID-19 adjacent spike in hydroxychloroquine use and increased reports of pemphigus: a disproportionality analysis of the FDA Adverse Event Reporting System
by: Justin Baroukhian, et al.
Published: (2024-12-01)

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database
by: Tingting Jiang, et al.
Published: (2025-01-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib
by: Yi Yin, et al.
Published: (2024-11-01)

Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008–2017
by: Ha-Lim Jeon, et al.
Published: (2021-08-01)

A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
by: Ya-Jun Zhang, et al.
Published: (2024-12-01)

Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
by: Luyang Su, et al.
Published: (2024-12-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01)

A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
by: Dongdong Zhang, et al.
Published: (2024-12-01)

The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.
by: Lufeng Peng, et al.
Published: (2024-01-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Evaluation of anticancer therapy- related dermatologic adverse events: insights from fda's faers dataset
by: S. Salah, et al.
Published: (2024-01-01)

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database
by: Hunong Xiang, et al.
Published: (2025-01-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study
by: Jing Huang, et al.
Published: (2023-08-01)

Drug Safety During Breastfeeding: A Comparative Analysis of FDA Adverse Event Reports and LactMed<sup>®</sup>
by: Hülya Tezel Yalçın, et al.
Published: (2024-12-01)

Exploratory disproportionality analysis of potentially drug-induced eosinophilic pneumonia using United States Food and Drug Administration adverse event reporting system
by: Ashwin Kamath
Published: (2025-01-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

Antibiotics-induced pulmonary embolism: A disproportionality analysis in Food and Drug Administration database of Adverse Event Reporting System using data mining algorithms
by: Pramod Kumar Adusumilli, et al.
Published: (2025-01-01)

Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile
by: Astri Budikayanti, et al.
Published: (2018-01-01)

Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
by: Chengliang Wang, et al.
Published: (2024-12-01)

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system
by: Yanjun Lu, et al.
Published: (2024-12-01)